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ABSTRACT 
Background: We investigated cancer risk among patients with multiple sclerosis (MS) and whether 
variation by age at MS diagnosis helps to elucidate mechanisms underlying the previously re­
ported reduced cancer risk. We also studied cancer risk among parents to ascertain if MS suscep­
tibility genes may confer protection against cancer in relatives. 
Methods: Cox proportional hazards regression, adjusted for age, sex, area, and socioeconomic 
index, estimated cancer risk among 20,276 patients with MS and 203,951 individuals without 
MS, using Swedish general population register data. Similar analyses were conducted among 
11,284 fathers and 12,006 mothers of patients with MS, compared with 123,158 fathers and 
129,409 mothers of controls. 
Results: With an average of 35 years of follow-up, there was a decreased overall cancer risk 
among patients with MS (hazard ratio = 0.91, 0.87–0.95). Increased risks were observed for 
brain tumors (1.44, 1.21–1.72) and urinary organ cancer (1.27, 1.05–1.53). Parents of patients 
with MS did not have a notably increased or decreased overall cancer risk. 
Conclusions: The reduction in cancer risk in patients with multiple sclerosis (MS) may result from 
behavioral change, treatment, or we speculate that some immunologic characteristics of MS dis­
ease activity improve antitumor surveillance. The lack of association among parents indicates 
that a simple inherited characteristic is unlikely to explain the reduced cancer risk among patients 
with MS. MS is associated with increased risk for some cancers, such as of urinary organs and 
brain tumors (although surveillance bias may be responsible). Neurology® 2009;72:1170–1177 
GLOSSARY 
CI = confidence interval; HR = hazard ratio; MS = multiple sclerosis. 
Cancer risk among patients with multiple sclerosis (MS) is important, as they may be 
subject to immunomodulatory therapies potentially altering cancer risk. A large Danish 
study1 and some smaller studies2-4 reported a lower overall cancer risk in MS, although 
there are contradictory results.5 MS has been associated with a reduced risk for digestive, 
respiratory, prostate, and ovary cancers1 and non-Hodgkin lymphoma6 but increased risks 
for urinary tract and nasopharyngeal cancers.1 Breast cancer risk has been reported as 
higher,1,4 lower,3 or unchanged.2,5 
Besides assessing cancer risk in a nationally representative group of patients with MS diagnosed 
over several decades with long follow-up and general population-based controls, this article is con­
cerned with establishing if any reduced cancer risk is due to changes following disease onset. This 
could include lifestyle changes following diagnosis, or immunologic changes due to disease activity: 
these influences may not be mutually exclusive and younger age at MS onset could confer greater 
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protection. Some genetic MS susceptibility fac­
tors may also protect against cancer. Reduced 
cancer risk among parents of patients with MS 
would be consistent with this genetic explana­
tion. As inflammation increases cancer risk,7 we 
hypothesized that patients with MS are at 
higher risk of brain tumors due to chronic 
neurologic inflammation. 
METHODS Patients who received a diagnosis of MS in Swe­
den between 1969 and 2005 were identified using the national 
Inpatient Register,8 which records the discharge diagnoses of all 
inpatients in Sweden, and the national Swedish Multiple Sclero­
sis Register, which requires written informed consent for inclu­
sion.9 To assess diagnostic accuracy, we randomly sampled 112 
patients in the MS Register, and after excluding suspected MS as 
identified in the register, the diagnosis was confirmed in 105/ 
109; 96% (95% confidence interval [CI]: 91–99%). 
Subjects with MS were individually matched with 12 indi­
viduals (fewer in a small minority) without the disease among 
the general Swedish population by Statistics Sweden. The 
matching criteria for controls were year of birth, sex, vital status, 
region of residence (the 24 counties of Sweden), and age at the 
time of diagnosis in the matched case. The Multi-Generation 
Register10 was used to identify both biological parents of sub­
jects. The Swedish migration and death registers have provided 
information on date of migration or death among index subjects 
and their parents. We used the national Swedish Cancer Register 
to identify the date and diagnosis of cancer among cases, con­
trols, and their parents. This register was established in 1958 and 
records all newly diagnosed malignant tumors in Sweden, and 
reportedly over 98% complete.11 All health care providers in 
Sweden are obliged to report newly detected cancer diagnoses. 
The Cancer Register used ICD-7 codes and a WHO pathology 
code where applicable. 
A six-category socioeconomic index was based on occupation 
identified from the census nearest in time to study entry (manual 
workers, nonmanual workers, professionals, self employed, farm­
ers, and others). All data were linked using the unique personal 
identity number issued to all Swedish residents. 
From among 20,543 cases and 204,163 controls, we ex­
cluded 267 cases and 212 controls due to missing informa­
tion. We had information on biological fathers for 11,284 
cases with MS and 123,158 controls, and biological mothers 
for 12,006 cases and 129,409 controls. There were no differ­
ences in the demographic characteristics of subjects with and 
without MS when those with linked data on mothers and 
fathers were compared with those who did not have linked 
data. Index subjects (with MS and the comparison group 
without MS) with linked data had a higher mean age at exit 
(69 years compared with 50 years), and longer follow-up time 
(39 years compared with 29 years). This is mainly because 
those without linked data for parents were born earlier and 
censored at an earlier timepoint. They could not be linked to 
their parents because they were born before 1932 or their 
parents died before 1947, the time that the unique personal 
identity number was first issued.10 It is important to note that 
the parents of cases and controls who entered the study had 
the same age distribution at final follow-up, average age at 
diagnosis of cancer, and average follow-up time (table 1). 
Therefore, there was nothing to indicate differential bias be­
tween cases and controls. 
This study was approved by the Karolinska Institutet re­
gional ethics committee. 
Statistical analysis. Cox proportional hazard regression was 
used to estimate the risk of cancer among patients with MS 
and their parents. The cohorts of parents were those with or 
without offspring with MS. Follow-up was from 1958, when 
the Cancer Register was established, or from birth or immi­
gration if this occurred subsequently. Follow-up continued 
until diagnosis of any cancer, death, emigration, or December 
31, 2005. The results are for the risk of first primary cancer 
and we excluded all benign tumors and cancers found inci­
dentally at autopsy. The underlying time scale for all models 
was attained age, and adjustment was for the matching char­
acteristics used to define risk-sets and socioeconomic index. 
To prevent bias due to birth cohort effects and to tackle pos­
sible temporal changes in the delay between age at symptom 
onset and age at diagnosis, we included period (in 10-year 
intervals) in the strata statement of the Cox regression 
analysis. 
Risks for specific cancer diagnoses and overall cancer risk 
were estimated. The analyses were stratified by sex (separate anal­
ysis for each sex). Similar stratified analyses restricted data to risk 
sets where the MS diagnosis was below age 20 years, 20–34 
years, or over age 34 years. These cutpoints were chosen to en­
sure a reasonable number of events in each group. Other strati­
fied analyses were by follow-up time (<5, 5–19, '20 years) and 
calendar year of study entry (before or after 1980). Further anal­
ysis used period (in years) as the underlying time scale to exam­
ine temporal trends in the association of MS with cancer risk 
using Cox regression. 
Some analyses restricted to the patients identified in the MS 
register (7,957 with MS and 89,078 without) to ensure diagnos­
tic misclassification did not bias our results. 
All analyses were repeated after exclusion of families where 
either parent had a diagnosis of MS. The assumption of propor­
tionality was verified for all analyses by using models allowing 
calculation of time-dependent risk ratios. 
All analyses used SAS statistical software. 
RESULTS The study population is described in ta­
ble 1 and includes 20,276 patients with MS (65.2% 
women) and 203,951 subjects without the disease. 
Some 29.3% and 2.0% of patients with MS were 
censored due to death and emigration, and the corre­
sponding percentages for subjects without the disease 
were 15.9% and 4.1%. The analysis of parents used 
information on 11,284 fathers and 12,006 mothers 
of patients with MS, with 123,158 fathers and 
129,409 mothers of index subjects without MS. 
Cancer risk among patients with MS. The overall risk 
of cancer was significantly lower among subjects with 
MS than among the comparison group (table 2), par­
ticularly among women. When follow-up began at 
date of MS diagnosis, the overall estimate was little 
changed, producing a hazard ratio (HR) (95% CI) of 
0.88 (0.84 –0.93). When restricted to MS register 
subjects (and the relevant comparison cohort) the 
risk was lower (HR = 0.63, 95% CI 0.55–0.72). 
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Table 1 Characteristics of the patients with MS, controls, and parents 
Index subjects Fathers Mothers 
Cases (%) Controls (%) Cases (%) Controls (%) Cases (%) Controls (%) 
Total no. 20,276 203,951 11,284 123,158 12,006 129,409 
Sex 
Male 7,058 (34.8) 71,313 (35.0) — — — —
 
Female 13,218 (65.2) 132,638 (65.0) — — — —
 
Age at MS diagnosis/entry, y
 
<20 440 4,582 — — — —
 
20–34 4,467 45,969 — — — —
 
>35 15,369 153,396 — — — —
 
Age at final follow-up, y 
<10 22 (0.1) 233 (0.1) — — — — 
10–19 76 (0.4) 883 (0.4) — — 2 (0.02) 29 (0.02) 
20–29 804 (4.0) 9,291 (4.6) 26 (0.2) 235 (0.2) 25 (0.2) 234 (0.2) 
30–39 2,056 (10.1) 21,506 (10.5) 95 (0.8) 920 (0.8) 82 (0.7) 754 (0.6) 
40–49 3,407 (16.8) 31,655 (15.5) 307 (2.7) 3,524 (2.9) 371 (3.1) 3,892 (3.0) 
50–59 4,592 (22.7) 40,421 (19.8) 1,361 (12.1) 14,870 (12.1) 1,500 (12.5) 15,727 (12.2) 
60–69 4,372 (21.6) 38,628 (18.9) 2,777 (24.6) 30,306 (24.6) 2,567 (21.4) 28,045 (21.7) 
70–79 3,220 (15.9) 31,661 (15.5) 3,528 (31.3) 38,225 (31.0) 3,285 (27.4) 35,883 (27.7) 
>80 1,727 (8.5) 29,673 (14.6) 3,190 (28.3) 35,078 (28.5) 4,174 (34.8) 44,845 (34.7) 
Mean age, y 57.4 58.9 71.6 71.7 72.8 72.9 
Average age at diagnosis 61.0 63.0 70.2 70.2 65.9 66.3
 
of cancer, y
 
Average follow-up time, y 35.1 35.3 28.4 28.8 32.6 32.9
 
Socioeconomic index, %
 
Manual workers 20.0 27.7 43.3 43.3 33.6 34.0 
Nonmanual workers 23.2 27.1 26.0 26.0 30.2 30.1 
Professionals 0.3 0.4 3.3 3.3 2.6 2.6 
Farmers 0.7 1.6 9.3 9.3 8.6 8.9 
Self-employed 2.2 3.1 7.9 8.1 6.2 6.8 
Other 52.3 40.1 7.5 7.2 17.5 16.6 
Missing 1.2 0.1 2.7 2.3 1.3 1.2 
MS = multiple sclerosis. 
Site-specific analysis (table 2) found point esti- Stratification by age at MS diagnosis found a 
mates for the majority of cancers below unity, sig- lower overall cancer risk among those diagnosed at 
nificant for cancers of the stomach, pancreas, lung, an earlier age, with HRs (95% CI) of 0.32 (0.10 – 
ovary, prostate, and lymphoma, but small num- 0.99), 0.64 (0.54 – 0.75), and 0.92 (0.88 – 0.96) 
bers prevented meaningful interpretation when for diagnosis at ages under 20, 20 –34, and over 34 
stratified by sex. Brain tumor and urinary organ years. This effect was more pronounced among 
cancer risk was significantly increased. The aver- women, such that an interaction test of age (mod­
age age at brain tumor diagnosis was 51.4 years eled continuously) by sex produced a hazard ratio 
among patients with MS and 53.2 years in the of 0.974 (0.972– 0.976) and p < 0.0001. How-
comparison cohort. Further evidence of potential ever, no difference in cancer risk by age, for men 
surveillance bias comes from examination of histo- or women, was observed for age at symptomatic 
logic diagnosis, as there were more diagnoses of MS onset among a subset of 6,811 patients from 
benign meningioma among patients with MS with the MS Register with these data and 76,165 from 
brain tumors (35.6%), compared with 29.2% the comparison cohort (data not shown). 
among the comparison cohort. There was no clear There was no conspicuous variation in cancer risk 
excess of malignant tumors in those with MS. when the analysis was stratified by follow-up time. 
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Table 2 Risk of first cancer among patients with multiple sclerosis compared with controls 
Men: 7,058 cases and 71,313 Women: 13,218 cases and 132,638 All: 20,276 cases and 203,951 
controls controls controls 
Cancer site (ICD-7 code) Events HR (95% CI) Events HR (95% CI) Events HR (95% CI)
 
All cancer (140–209) 723/10,616 0.94 (0.87–1.02) 1,416/18,270 0.88 (0.84–0.93) 2,139/28,886 0.91 (0.87–0.95)
 
Digestive cancer 145/2,290 0.90 (0.76–1.06) 207/3,312 0.77 (0.67–0.89) 352/5,602 0.83 (0.75–0.93)
 
(150–159) 
Esophageal (150) 7/140 0.71 (0.33–1.52) 5/73 0.90 (0.36–2.24) 12/213 0.76 (0.42–1.37) 
Stomach (151) 20/395 0.72 (0.46–1.12) 14/388 0.45 (0.26–0.76) 34/783 0.62 (0.45–0.85) 
Small intestine (152) 8/45 2.43 (1.14–5.19) 8/80 1.22 (0.59–2.53) 16/125 1.63 (0.98–2.72) 
Large intestine (153) 44/702 0.88 (0.65–1.20) 99/1,286 0.96 (0.78–1.17) 143/1,988 0.98 (0.83–1.15) 
Rectum (154) 35/501 0.96 (0.68–1.36) 37/598 0.76 (0.54–1.05) 72/1,099 0.88 (0.70–1.11) 
Biliary passage and liver 17/204 1.23 (0.75–2.03) 23/417 0.70 (0.46–1.06) 40/621 0.92 (0.68–1.25) 
(155)
 
Liver cancer unspecified 0/37 Not estimated 3/61 0.62 (0.19–1.97) 3/98 0.39 (0.12–1.25)
 
(156) 
Pancreatic (157) 14/259 0.78 (0.46–1.35) 18/402 0.55 (0.34–0.88) 32/661 0.67 (0.48–0.94) 
Respiratory cancer 59/1,051 0.77 (0.59–1.00) 60/1,094 0.64 (0.49–0.83) 119/2,145 0.69 (0.58–0.82) 
(160–164) 
Trachea, bronchus, lung 47/912 0.71 (0.53–0.96) 56/1,001 0.65 (0.49–0.84) 103/1,913 0.66 (0.55–0.80) 
(162) 
Breast cancer (170) — — 451/5,174 0.95 (0.86–1.05) 454/5,197 0.96 (0.87–1.05) 
Cervix uteri cancer (171) — — 63/795 0.83 (0.64–1.07) 63/795 0.83 (0.64–1.07) 
Corpus uteri cancer (172) — — 92/1,011 1.08 (0.88–1.32) 92/1,011 1.08 (0.88–1.32) 
Ovarian cancer (175) — — 55/1,047 0.58 (0.45–0.76) 55/1,047 0.58 (0.45–0.76) 
Prostate cancer (177) 159/2,923 0.80 (0.69–0.94) — — 159/2,923 0.80 (0.69–0.94) 
Testis cancer (178) 7/134 0.47 (0.21–1.06) — — 7/134 0.47 (0.21–1.06) 
Kidney cancer (180) 24/335 0.92 (0.61–1.40) 26/403 0.78 (0.52–1.16) 50/738 0.93 (0.72–1.21) 
Urinary organ cancer ex. 63/778 1.12 (0.87–1.45) 42/347 1.50 (1.09–2.07) 105/1,125 1.27 (1.05–1.53) 
kidney (181)
 
Brain tumors (193) 50/311 1.96 (1.46–2.64) 81/731 1.18 (0.93–1.48) 131/1,042 1.44 (1.21–1.72)
 
Thyroid cancer (194) 2/52 0.47 (0.11–1.92) 24/245 1.04 (0.69–1.59) 26/297 1.01 (0.69–1.50)
 
Endocrine cancer (195) 13/131 1.19 (0.67–2.11) 49/440 1.21 (0.90–1.63) 62/571 1.21 (0.93–1.55)
 
Bone cancer (196) 2/21 1.15 (0.27–4.94) 1/34 0.31 (0.04–2.23) 3/55 0.55 (0.17–1.75)
 
Connective tissue cancer 9/80 1.47 (0.73–2.94) 6/128 0.51 (0.23–1.17) 15/208 0.88 (0.54–1.44)
 
(197)
 
Lymphoma (200–202, 205) 39/560 0.89 (0.65–1.24) 43/741 0.67 (0.50–0.92) 82/1,301 0.76 (0.61–0.94)
 
Melanoma skin cancer (190) 33/385 1.03 (0.72–1.47) 50/732 0.74 (0.55–0.98) 83/1,117 0.82 (0.66–1.02)
 
Nonmelanoma skin cancer 35/480 1.12 (0.80–1.59) 46/448 1.37 (1.01–1.86) 81/928 1.13 (0.91–1.40)
 
(191)
 
Eye cancer (192) 3/34 1.04 (0.32–3.40) 2/32 0.66 (0.16–2.77) 6/66 0.91 (0.39–2.10)
 
Nose, middle ear cancer 18/344 0.73 (0.45–1.17) 44/616 0.89 (0.66–1.21) 62/960 0.85 (0.66–1.08)
 
(160) 
The model was adjusted for age, sex, region of residence, and socioeconomic index. 
CI = confidence interval; HR = hazard ratio. 
When calendar year was used to examine the asso- no association between MS and cancer risk be­
ciation of MS with overall cancer risk, there was tween 1958 and 1969, then the risk subsequently 
almost no temporal variation between 1970 and reduced. 
final follow-up in 2005, with no evidence of a con- Excluding index subjects with a parent with 
sistent change in gradient. Follow-up began in MS did not materially change any of the results 
1958 with the inception of the cancer register, but (data not shown). The estimates for overall cancer 
as the MS Register began in 1969, there were few risk (HR = 0.85, 95% CI 0.79 – 0.92) and site-
events in the early period, such that there was specific cancers were almost identical when the 
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Table 3 Risk of first cancers among parents of patients with multiple sclerosis compared with parents 
of controls 
Fathers Mothers 
Cancer site Events HR (95% CI) Events HR (95% CI)
 
All cancer 2,834/30,019 1.03 (0.99–1.07) 2,626/27,749 1.02 (0.98–1.06)
 
Digestive cancer 667/7,134 1.03 (0.95–1.11) 562/5,990 1.02 (0.93–1.11)
 
Esophageal 27/376 0.89 (0.60–1.32) 7/122 0.63 (0.30–1.36) 
Stomach 130/1,594 0.90 (0.75–1.08) 90/785 1.25 (1.00–1.55) 
Small intestine 16/136 1.29 (0.77–2.17) 12/121 1.08 (0.59–1.95) 
Large intestine 203/2,052 1.08 (0.94–1.25) 215/2,133 1.09 (0.94–1.25) 
Rectum 135/1,406 1.05 (0.88–1.25) 97/1,133 0.93 (0.76–1.15) 
Biliary passage and liver 65/627 1.14 (0.89–1.48) 55/837 0.71 (0.54–0.93) 
Liver, unspecified 6/120 0.55 (0.24–1.26) 13/101 1.39 (0.78–2.48) 
Pancreatic 85/852 1.09 (0.87–1.36) 72/743 1.05 (0.82–1.34) 
Respiratory cancer 289/3,317 0.94 (0.83–1.06) 133/1,409 1.04 (0.87–1.24) 
Trachea, bronchus, lung 248/2,880 0.93 (0.82–1.06) 117/1,267 1.02 (0.84–1.23) 
Breast cancer — — 648/6,922 1.02 (0.94–1.10) 
Cervix uteri cancer — — 132/1,207 1.18 (0.98–1.41) 
Corpus uteri cancer — — 162/1,614 1.10 (0.94–1.29) 
Ovarian cancer — — 117/1,368 0.93 (0.77–1.12) 
Prostate cancer 790/8,596 1.01 (0.94–1.09) — — 
Testis cancer 10/124 0.80 (0.41–1.58) — — 
Kidney cancer 117/1,049 1.23 (1.02–1.49) 80/814 1.07 (0.85–1.34) 
Urinary organ cancer ex. kidney 194/2,109 1.01 (0.87–1.17) 57/637 0.97 (0.74–1.28) 
Brain tumors 77/707 1.19 (0.94–1.51) 80/917 0.95 (0.75–1.19) 
Thyroid cancer 14/139 1.11 (0.64–1.92) 30/330 0.96 (0.66–1.40) 
Endocrine cancer 34/284 1.32 (0.93–1.89) 81/679 1.26 (1.00–1.59) 
Bone cancer 8/38 2.47 (1.15–5.32) 2/41 0.27 (0.04–1.97) 
Connective tissue cancer 16/191 0.93 (0.56–1.55) 16/186 0.93 (0.56–1.56) 
Lymphoma 148/1,356 1.20 (1.01–1.42) 95/1,183 0.86 (0.70–1.07) 
Melanoma skin cancer 79/774 1.10 (0.87–1.39) 90/801 1.22 (0.98–1.52) 
Nonmelanoma skin cancer 112/1,316 0.94 (0.77–1.14) 77/848 0.97 (0.77–1.23) 
Eye cancer 11/85 1.39 (0.74–2.61) 6/60 1.09 (0.47–2.52) 
Nose, middle ear cancer 92/887 1.10 (0.89–1.37) 107/1,125 1.03 (0.84–1.25) 
The model was adjusted for parents’ age, sex of the index person, region of residence, and socioeconomic index. 
analysis examined all cancer diagnoses instead of cancer diagnosis (1.03, 0.99 –1.07 for fathers; 1.02, 
first cancer diagnosis (data not shown). 0.98 –1.06 for mothers). 
Cancer risk among the biological parents of patients 
DISCUSSION This large general population-based with MS. There was no overall increased or decreased 
register study of patients with MS and their parents risk of cancer among either mothers or fathers of 
confirmed a reduction in cancer risk of approxi­those with MS, compared with parents of index sub­
mately 10% among those with MS and this effect jects without MS (table 3). The site-specific analysis 
was more pronounced among women. A raised risk did not indicate any overall pattern of protection or 
was observed for some specific cancers including risk. There was a modest risk increase for cancers of 
bone, kidney, and lymphoma among fathers, and en- brain tumors and cancer of the urinary organs. No 
docrine cancers among mothers. notable pattern of cancer risk or protection was ob-
The estimates for overall cancer risk and site- served among parents of those with MS. 
specific cancers were almost identical when the anal- The cancer risk reduction among patients with 
ysis examined all cancer diagnoses, rather than first MS is consistent with previous studies,1-5 demon­
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strating decreased risks for cancers of the digestive 
system, respiratory system, ovary, and prostate.1 We 
also identified notably reduced risk for stomach and 
pancreatic cancers. As there were fewer men, this 
limited precision for estimating risk of less common 
cancers among men. 
An evolutionary hypothesis is that genetic factors 
protect from cancer but only result in MS after spe­
cific triggering events, leading to their persistence in 
the gene pool. However, the results from parents of 
those with MS suggest this explanation is unlikely. 
There was a modest risk increase for cancers of bone, 
kidney, and lymphoma among fathers, and endo­
crine cancers among mothers. While these could be 
chance results (due to a few events), genetic or envi­
ronmental factors relevant to MS risk in offspring 
might also explain these findings. A Danish study12 
reported familial clustering of young adult onset 
Hodgkin lymphoma in first-degree relatives of pa­
tients with MS (RR = 1.93), consistent with the 
paternal lymphoma risk identified here. We cannot 
rule out a genetic basis for cancer protection due to 
differences in gene expression between parents and 
offspring. 
The lower cancer risk among patients with MS 
could be associated with lifestyle changes, treatment, 
disease-related activity, or a combination of these fac­
tors. Behaviors could include smoking; we have no 
information on smoking, but it is notable that several 
studies have found that smoking prevalence is mod­
estly increased in MS.13-15 This suggests the reduc­
tion in lung and other cancer risks may exist despite 
some increase in tobacco smoke exposure. Bladder 
cancer is also associated with smoking, so its in­
creased risk is in contrast with that for lung cancer. 
We speculate that the association with urinary blad­
der cancer is consistent with chronic irritation due to 
micturition problems and urinary infections experi­
enced by patients with MS. Patients with MS have 
on average a lower body mass index than the general 
population16 and body mass index is a risk factor for 
several cancer types,17 so lower body weight may ex­
plain some cancer risk reduction. Other behavioral 
changes or exposures following diagnosis may also be 
relevant; however, few known behavioral factors have 
been linked with pancreatic or prostate cancer. We 
speculate that cancer protection might partly result 
from the increase in systemic autoimmune responses 
as against myelin antigens observed among patients 
with MS.18 If autoimmune cells such as these react 
specifically against tumor autoantigens, this could 
represent an effective tumor defense mechanism. The 
existence of such mechanisms is well established in 
paraneoplastic autoimmune phenomena like the 
Eaton-Lambert syndrome, where anti-channel anti­
bodies cross-react with lung tumors, thus controlling 
them. Unlike MS, rheumatoid arthritis—another 
autoimmune disease—is associated with a modest in­
crease in overall cancer risk and for lymphoma and 
lung cancer but also some decreased risks.19 
The observed increase in brain tumor risk may be 
due to neurologic inflammation as chronic inflam­
mation is a recognized cancer risk.7 Other studies did 
not identify an increased risk, perhaps due to shorter 
follow-up time1 or fewer events.4 Surveillance bias, 
due to frequent neuro-radiologic examinations, may 
be responsible for this finding as there was no clear 
excess of malignant brain tumors among patients 
with MS. We found moderate increased risks for 
cancers of urinary organs and nonmelanoma skin 
cancer among women and a more than twofold in­
creased risk of small intestine cancer among men. It 
is notable that there is no increase in thyroid cancer 
risk, as there is comorbidity between MS and 
immune-mediated inflammation of this organ. 
While immunomodulatory therapy used in MS 
could potentially increase cancer risk,2,3,20,21 this is an 
unlikely explanation for cancer in these specific sites, 
as immunosuppressive drugs such as azathioprine 
and cyclophosphamide are used extremely rarely for 
MS in Sweden. Since approximately 1993, there has 
been an increase in the use of interferon beta drugs. 
However, as there was no notable change in cancer 
risk associated with MS after this timepoint, it does 
not indicate greater risk due to the introduction of 
these therapies. 
It could be argued that the observed lower overall 
cancer risk is because patients with MS may have 
shorter life expectancy than the general popul­
ation,22-24 with an average of approximately 5 to 10 
years of life lost.25 This is unlikely to be a major fac­
tor here as the Cox models estimated age-specific 
risks and hazard ratios. Masking of cancer symptoms 
and signs by MS is another unlikely explanation for 
our results, as those with a chronic disease such as 
MS are more likely to undergo frequent investiga­
tions. Overestimation of cancer risk among patients 
with MS is more likely, due to potential surveillance 
bias. Our main analyses were of first cancer diag­
nosed in an individual, but the results were similar 
when the analysis was extended to all cancers. As the 
national Swedish Cancer Register is more than 98% 
complete,11 this reduces the risk of information bias. 
As this register began in 1958, earlier diagnoses 
would be missed: stratification by year of birth (be­
fore of after 1958) demonstrated this was not a prob­
lem. A potential limitation is the lack of information 
on behavior, such as drinking, smoking, and exercise. 
To tackle this issue we were able to adjust for a mea­
sure of socioeconomic circumstances (which is 
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strongly associated with many behaviors), as well as 
for region of residence and period. 
The reduced cancer risk associated with age at di­
agnosis is equivocal as no association was observed 
for age at symptomatic MS onset. This may be a 
chance finding or because information on symptom­
atic onset is less precise and available only for a sub­
set. Another possibility is that age at diagnosis is a 
proxy marker of disease phenotype or severity, not 
reflected by onset age. 
The diagnostic accuracy of MS could be a con­
cern.26 There is evidence of relatively high diagnostic 
accuracy for MS among patients included in the 
Multiple Sclerosis Register. Those with suspected 
MS are excluded and among a sample, 92% (2,933) 
had positive test results for CSF oligoclonal bands, 
consistent with the diagnosis with over 95% specific­
ity after the usual exclusion criteria,27 with similar 
indication of diagnostic specificity from MRI find­
ings. However, these data were only available for 
64% of the patients with MS; they are less frequently 
available for patients diagnosed in earlier periods, 
particularly before the mid-1970s. 
While there is greater evidence of high diagnostic 
specificity among patients who entered or remained 
in the Register during the later period, the temporal 
pattern of association between MS and cancer risk 
does not indicate that substantial variation in MS 
specificity accounts for the results. Our review of 112 
randomly chosen patient records further indicates a 
high degree of diagnostic accuracy of 96% for the 
MS Register, suggesting that the other signs of diag­
nostic accuracy for this register are not a function of 
selection bias. A diagnosis of MS is likely to be less 
specific for the Inpatient Register and include pa­
tients with a suspected rather than confirmed diag­
nosis, as well as being influenced potentially by other 
sources of error. Other diseases such as Crohn disease 
have revealed diagnostic accuracy of around 85%.28 
MS diagnoses are likely to be more reliable in the MS 
Register, consistent with the greater reduction in 
cancer risk in this subset of patients. 
AUTHOR CONTRIBUTIONS 
The statistical analyses were conducted by Shahram Bahmanyar and Scott 
M. Montgomery. 
Received August 6, 2008. Accepted in final form January 16, 2009. 
REFERENCES 
1.	 Nielsen NM, Rostgaard K, Rasmussen S, et al. Cancer risk 
among patients with multiple sclerosis: a population-based 
register study. Int J Cancer 2006;118:979–984. 
2.	 Achiron A, Barak Y, Gail M, et al. Cancer incidence in 
multiple sclerosis and effects of immunomodulatory treat­
ments. Breast Cancer Res Treat 2005;89:265–270. 
3.	 Lebrun C, Debouverie M, Vermersch P, et al. Cancer risk 
and impact of disease-modifying treatments in patients 
with multiple sclerosis. Mult Scler 2008;14:399–405. 
4.	 Midgard R, Glattre E, Gronning M, Riise T, Edland A, 
Nyland H. Multiple sclerosis and cancer in Norway: a ret­
rospective cohort study. Acta Neurol Scand 1996;93:411– 
415. 
5.	 Sumelahti ML, Pukkala E, Hakama M. Cancer incidence 
in multiple sclerosis: a 35-year follow-up [see comment]. 
Neuroepidemiology 2004;23:224–227. 
6.	 Soderberg KC, Jonsson F, Winqvist O, Hagmar L, 
Feychting M. Autoimmune diseases, asthma and risk of 
haematological malignancies: a nationwide case-control 
study in Sweden. Eur J Cancer 2006;42:3028–3033. 
7.	 Tan TT, Coussens LM. Humoral immunity, inflamma­
tion and cancer. Curr Opin Immunol 2007;19:209–216. 
8.	 The Swedish Hospital Discharge Register 1987–1996: 
Quality and Contents. Stockholm: The National Board of 
Health and Welfare; 1998. 
9.	 Hillert J. Available at: http://www.kvalitetsregister.se/ 
images/stories/register_2007/15_svenska_multipel_skleros_ 
registret_sms-registret.pdf. Available. Accessed June 16, 2008. 
10.	 Statistics-Sweden. Bakgrundsfakta till befolknings: och 
va¨lfa¨rdsstatistik (The Multi-Generation Registry). O¨ rebro: 
Statistics Sweden; 2001. 
11.	 Mattsson B, Wallgren A. Completeness of the Swedish 
Cancer Register: non-notified cancer cases recorded on 
death certificates in 1978. Acta Radiol Oncol 1984;23: 
305–313. 
12.	 Hjalgrim H, Rasmussen S, Rostgaard K, et al. Familial 
clustering of Hodgkin lymphoma and multiple sclerosis. 
J Natl Cancer Inst 2004;96:780–784. 
13.	 Hawkes CH. Smoking is a risk factor for multiple sclerosis: 
a metaanalysis. Mult Scler 2007;13:610–615. 
14.	 Hernan MA, Jick SS, Logroscino G, Olek MJ, Ascherio A, 
Jick H. Cigarette smoking and the progression of multiple 
sclerosis. Brain 2005;128:1461–1465. 
15.	 Riise T, Nortvedt MW, Ascherio A. Smoking is a risk 
factor for multiple sclerosis. Neurology 2003;61:1122– 
1124. 
16.	 Nortvedt MW, Riise T, Maeland JG. Multiple sclerosis 
and lifestyle factors: the Hordaland Health Study. Neurol 
Sci 2005;26:334–339. 
17.	 Ceschi M, Gutzwiller F, Moch H, Eichholzer M, 
Probst-Hensch NM. Epidemiology and pathophysiol­
ogy of obesity as cause of cancer. Swiss Med Weekly 
2007;137:50–56. 
18.	 Olsson T, Zhi WW, Hojeberg B, et al. Autoreactive T 
lymphocytes in multiple sclerosis determined by antigen-
induced secretion of interferon-gamma. J Clin Invest 
1990;86:981–985. 
19.	 Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-
analysis of the incidence of malignancy in adult patients with 
rheumatoid arthritis. Arthritis Res Ther 2008;10:R45. 
20.	 Confavreux C, Saddier P, Grimaud J, Moreau T, Adeleine 
P, Aimard G. Risk of cancer from azathioprine therapy in 
multiple sclerosis: a case-control study. Neurology 1996; 
46:1607–1612. 
21.	 De Ridder D, van Poppel H, Demonty L, et al. Bladder 
cancer in patients with multiple sclerosis treated with cy­
clophosphamide. J Urol 1998;159:1881–1884. 
22.	 Bronnum-Hansen H, Koch-Henriksen N, Stenager E. 
Trends in survival and cause of death in Danish patients 
with multiple sclerosis. Brain 2004;127:844–850. 
1176 Neurology 72 March 31, 2009 
23. Hirst C, Swingler R, Compston A, Ben-Shlomo Y, 
Robertson NP. Survival and cause of death in multiple 
sclerosis: a prospective population-based study. J Neurol 
Neurosurg Psychiatry 2008;79:1016–1021. 
24. Koch-Henriksen N, Bronnum-Hansen H, Stenager E. 
Underlying cause of death in Danish patients with multi­
ple sclerosis: results from the Danish Multiple Sclerosis 
Registry. J Neurol Neurosurg Psychiatry 1998;65:56–59. 
25. Ragonese P, Aridon P, Salemi G, D’Amelio M, Savettieri 
G. Mortality in multiple sclerosis: a review. Eur J Neurol 
2008;15:123–127. 
26. Villar LM, Garcia-Barragan N, Sadaba MC, et al. Accu­
racy of CSF and MRI criteria for dissemination in space in 
the diagnosis of multiple sclerosis. J Neurol Sci 2008;266: 
27. 
34–37. 
Hillert J. Available at: http://www.kvalitetsregister.se/ 
images/stories/register/15-sms-registret/sms_arsrapport_ 
28. 
2005-2006.doc. Accessed November 19, 2008. 
Ekbom A, Helmick C, Zack M, Adami HO. The epide­
miology of inflammatory bowel disease: a large, 
population-based study in Sweden. Gastroenterology 
1991;100:350–358. 
Disagree? Agree? Have a Question? Have an Answer? 
Respond to an article in Neurology® through our online Correspondence system: 
• Visit www.neurology.org 
• Access specific article on which you would like to comment 
• Click on “Correspondence: Submit a response” in the content box 
• Enter contact information 
• Upload your Correspondence 
• Press “Send Response” 
Correspondence will then be transmitted to the Neurology Editorial Office for review. Correspon­
dence must be received within six weeks of the publication date of the article. Selected correspon­
dence will subsequently appear in the print Journal. See our Information for Authors at 
www.neurology.org for format requirements. 
Neurology 72 March 31, 2009 1177 
  
  
 
 
 
 
 
 
 
 
 
 
Cancer risk among patients with multiple sclerosis and their parents 
S. Bahmanyar, S. M. Montgomery, J. Hillert, et al.
 
Neurology 2009;72;1170
 
DOI 10.1212/01.wnl.0000345366.10455.62
 
This information is current as of August 25, 2012 
Services 
Updated Information & 
http://www.neurology.org/content/72/13/1170.full.html
including high resolution figures, can be found at: 
References 
1
http://www.neurology.org/content/72/13/1170.full.html#ref-list-
This article cites 24 articles, 9 of which can be accessed free at: 
Citations 
urls
http://www.neurology.org/content/72/13/1170.full.html#related-
This article has been cited by 15 HighWire-hosted articles: 
Subspecialty Collections 
Cohort studies 
http://www.neurology.org/cgi/collection/all_oncology
All Oncology 
http://www.neurology.org/cgi/collection/all_epidemiology
All epidemiology 
following collection(s): 
This article, along with others on similar topics, appears in the 
http://www.neurology.org/cgi/collection/primary_brain_tumor
Primary brain tumor 
http://www.neurology.org/cgi/collection/multiple_sclerosis
Multiple sclerosis 
http://www.neurology.org/cgi/collection/cohort_studies
Permissions & Licensing 
http://www.neurology.org/misc/about.xhtml#permissions
tables) or in its entirety can be found online at: 
Information about reproducing this article in parts (figures, 
Reprints
http://www.neurology.org/misc/addir.xhtml#reprintsus
Information about ordering reprints can be found online: 
